Tags : Protein-Based

Clinical Trials COVID-19

Sanofi and GSK Initiate P-II Study of their Adjuvanted Recombinant

Shots: The companies reported the initiation of a P-II dose-finding study assessing the safety, reactogenicity, and immunogenicity of two injections given 21 days apart in 720 adults aged ≥18yrs. The P-II study assesses the potential for refined antigen formulation to achieve an optimal immune response, including in older adults. If P-II results are positive, the […]Read More